Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 2.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This knowledge-based activity is approved for 2.25 contact hour (.225 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-18-011-L01-P).

Nursing (ANCC)
This activity is designated for 2.25 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Physician Assistants (AAPA)
Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

 

Objectives

At the conclusion of this application-based educational activity participants will be able to:

1. Appraise recent shifts in treatment patterns that have occurred in the management of anemia in CKD and the potential implications for patients and the healthcare system.

2. Evaluate current controversies in the safety of anemia management in CKD and the trial data that have led to increased precautions for this condition.

3. Examine the pathophysiology of anemia in kidney disease and how the role of hepcidin in iron metabolism contributes to this process.

4. Explore hypoxia-inducible factor (HIF) as a novel treatment target for anemia in CKD and the clinical trial safety and efficacy data that is available for investigational HIF-PH inhibitors.

5. Assess the therapeutic potential of HIF-PH inhibitors in myelodysplastic syndromes and review emerging clinical trial data.

6. Discuss the potential impact of HIF-PH inhibitors on clinical outcomes in CKD, MDS, etc. and explore how they compare to traditional ESAs and ESA biosimilars.

Target Audience

Hematologists, nephrologists, residents/fellows, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare providers attending the American Society of Hematology (ASH) 2018 Annual Meeting who manage patients with anemia.

Faculty Disclosure

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity. 

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners

Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Adrienne W. Matson, PharmD, BCPS—has no relevant financial relationships to disclose in relation to the content of this activity.

Presenters

Jeffrey S. Berns, MD-has no relevant financial relationships to disclose in relation to the content of this activity.

John A. Glaspy, MD, MPH-has no relevant financial relationships to disclose in relation to the content of this activity.

David H. Henry, MD-has no relevant financial relationships to disclose in relation to the content of this activity.

Ajay K. Singh, MBBS, FRCP, MBA-has disclosed that he is a consultant for GlaxoSmithKline.

Wendy St. Peter, PharmD, FASN, FCCP, FNKF-has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewers

Kirsten Jensen, DNP, ANP-BC, AG-ACNP-BC—has no relevant financial relationships to disclose in relation to the content of this activity.

Kim Zuber, PA-C—has no relevant financial relationships to disclose in relation to the content of this activity.